CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities
Net loss	$ (39,423)	$ (37,490)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	348	166
Amortization (accretion) on marketable securities	(182)	0
Non-cash interest expense	54	38
Non-cash lease expense	265	334
Stock-based compensation expense	5,321	5,378
Impairment of advance for COVAXIN supply	4,074	0
Loss on disposal of fixed assets related to COVAXIN	363	0
Other	439	0
Changes in assets and liabilities:
Prepaid expenses and other current assets	572	132
Accounts payable and accrued expenses	(8,625)	2,844
Lease obligations	(252)	(265)
Net cash used in operating activities	(37,046)	(28,863)
Cash flows from investing activities
Purchases of marketable securities	(3,947)	0
Proceeds from the maturities of marketable securities	17,500	0
Purchases of property and equipment	(4,389)	(1,589)
Net cash provided by (used in) investing activities	9,164	(1,589)
Cash flows from financing activities
Proceeds from issuance of common stock, net	20,690	50,538
Payment of equity issuance costs	(222)	(200)
Proceeds from issuance of debt	500	0
Payment of debt issuance costs	(68)	0
Net cash provided by financing activities	20,900	50,338
Effect of changes in exchange rate on cash and cash equivalents	(3)	10
Net (decrease) increase in cash and cash equivalents	(6,985)	19,896
Cash, cash equivalents, and restricted cash at beginning of period	77,563	95,109
Cash and cash equivalents at end of period	70,578	115,005
Supplemental disclosure of non-cash investing and financing transactions:
Equity issuance costs	133	69
Purchases of property and equipment	2,637	491
Right-of-use asset related to operating leases	$ 0	$ 2,918